Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where are you stashing all your millions and what is your sell price?
When it is low, so you can sell high!
$.69 AH
Time to buy low now and sell high next year!
Perhaps the CCAJ CEO (Pitre) should step down and let someone else run this company. Having failed to close any acquisitions and potentially having failed to gain company control (pending confirmation) is not a good way to run a company that touts "we have a remarkable set of expertise" on their website.
https://coastalcapitalacquisitioncorp.com/
Seems like CCAJ has un-engaged again. They definitely aren't communicating in a timely fashion through OTC Markets, Twitter, or the CCAJ website (which has outdated info).
They tried communicating actively via Twitter on March 31, 2023, then halted again except for 1 recent post on IHUB (if that was actually CCAJ Mgmt posting).
FROM TWITTER:
Coastal Capital Acquisition Corporation $CCAJ
@ccajstock
Mar 31
If you have any questions please send your request to shareholders@ccajstock.com, we will answer them to the best of our ability via the Investor Relations Page on our website.
Thank you,
Management
Coastal Capital Acquisition Corporation $CCAJ
@ccajstock
Mar 31
We at CCAJ will continue to utilize this method and form of communication to insure we stay within the Guidelines to make all information available to all shareholders at the same time.
Coastal Capital Acquisition Corporation $CCAJ
@ccajstock
Mar 31
We have just received a call from a shareholder that posed some questions and made us aware of these concerns and these questions and answers have been posted via our Investor Relations Page on our website. https://coastalcapitalacquisitioncorp.com/investor-relations/
Coastal Capital Acquisition Corporation $CCAJ
@ccajstock
Mar 31
We would like to inform all our valued shareholders that we have not been contacted for any information that we are permitted to respond to that we have not responded to.
Coastal Capital Acquisition Corporation $CCAJ
@ccajstock
Mar 31
Happy Friday $CCAJ Nation!
We have recently received notification that shareholders have been requesting information and our IR department has not been responsive.
After all the hoopla we got a website for our viewing pleasure. What more could we possibly want from the new management? Isn't that enough?
https://coastalcapitalacquisitioncorp.com/
Just a little cynical humor!
For the late filing notification, I think you are right that it pre-populates based on the 5 day rule. OTC Markets did change the CCAJ status to Limited Information shortly after the 5th day so now the question is how long until Current Information comes back. This will be the 3rd time in recent months.
As for the posting, I was also wondering if that was the company or someone else.
Needless to say, this week has been another interesting saga in the CCAJ (ad)venture. We'll see where it lands and whether Pitre and Company can make something of CCAJ after all these years.
Good point. Also, seems like the biggest question now is why hasn't CCAJ filed yet for the most recent quarter? They said they would file by March 20th.
The second biggest question is why did CCAJ reach out to Jaybee on IHUB? That is an interesting way to communicate about an issue brought up by an IHUB poster.
Looks like Pitre and Company have some explaining to do....or some tap dancing around this latest surprise!
Is this who you are referring to:
From the CCAC Website FAQs:
Why is Mr. Anthony DiNorcia listed on the OTC Markets Website after being removed in December 2021?
Mr. Anthony DiNorcia is no longer a part of the Executive Management Team thus his removal in December 2021. However, Mr. DiNorcia is listed on the OTC Markets website due to the requirements involving the number of Common Shares he currently holds.
PS: More recently DiNorcia is no longer on the OTC Markets Website.
Today is filing day. I don't see it yet so we shall see what happens next with CCAJ and the PPS! Hopefully the CEO finally has something good up his sleeve.
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or
Interim Report and 15 calendar days to post an Annual Report.]
May 20, 2023
Soon can range from 1 to 365 days or more! What is your actual speculative timeframe?
White Star Line built the Titanic so does this mean AXXA bought some memorabilia or a defunct shipping company?
Interesting filing today stating that "such delays are primarily due to management’s dedication of such management's time to business matters and the recent change in Company control." Hopefully they are actually getting some "business matters" completed!
Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period. Coastal Capital Acquisition Corporation (the “Company”) has been unable to complete its quarterly filing for the quarter ended March 31, 2023 within the prescribed time because of delays in completing the preparation of its financial statements and its management discussion and analysis. Such delays are primarily due to management’s dedication of such management's time to business matters and the recent change in Company control. This has taken a significant amount of management's time away from the preparation of the quarterly filing for the quarter ended March 31, 2023 and delayed the preparation of the unaudited financial statements for the quarter ended March 31, 2023.
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or Interim Report and 15 calendar days to post an Annual Report.]
May 20, 2023
Person to contact regarding this notification:
Date: 05/15/2023
Signature: /s/ William Pitre
Name: William Pitre
Title: Chief Executive Officer
44% UP GREEN! We'll see what color the next trading day has in store. CCAJ is definitely a rollercoaster between $.0009 and $.0015 these days. I wonder what Pitre and team are doing behind the scenes. Hopefully they are not planning another fiasco decision and announcement like they did in December 2022!
So, is it a fake resort on a fake island in a fake country?
The AXXA Phuket Serenity Lakeside Resort also has rooms you can book!
https://serenitykathu.com/
Yes, and #9 on the NASDAQ Most Active List today!
Yes, and top of the NASDAQ List today..........SBFM Sunshine Biopharma Inc 0.8900 0.3600 67.92% 69,628,938
27% DOWN RED! I knew it wouldn't last too long, but was fun while it lasted. Perhaps another GREEN day soon!
Yes, you are so right. Such an excellent direction for a stock. Looking forward to more in the coming days/weeks!
32% UP GREEN Today! I know it will only last a day or so on such low volume, but enjoyable to see for even 1 whole day! Thanks to whoever picked up a few.
Anything about NoraPharma? That acquisition was supposed to be their entry into revenue, but SBFM hasn't done any PRs about how the are doing/growing this year. The have a lot of sales managers and sales reps if you look at their website:
https://norapharma.ca/en/team/
And, it would be nice to know what these 4 people are doing to get CCAJ back on the fast track to success (as a company and the PPS)! CCAJ was on the fast track in 2021 and early 2022, but then slowed way, way, way down since June 2022, and more so since December 2022. Very strange indeed! We'll see what the rest of 2023 holds.
Rohn Monroe
Paul Jackson
Brian Nash
William Pitre
Well, the good news is CCAJ is Pink Current again. They were Pink Limited for the past few weeks. Looks like they had to continue revising the Annual Report and finally got it right (see below). Not sure why it took so many revisions, but this counts as one type of communication (via OTCMarkets Disclosures).
04/26/2023 Annual Report - CCAJ - Annual Audited Revised 2022 12/31/2022 A
04/05/2023 Annual Report - OO&OC Audited Revised 12/31/2022 A
03/30/2023 Annual Report - Annual Report CCAJ FY 2022 OTC Disclosure - Audited Corrected to New Guidelines 12/31/2022 A
03/28/2023 Annual Report - CCAJ FY 2022 - OTC Disclosure Audited 12/31/2022 A
Is this the "entire outfit" you are referring to? Are they all part of your conspiracy theory? You only mention Boris (who you seem to refer to as Doris) by name.
Dr. Eduard Nazmiev
Chairman of the Board, CEO, CFO
Dr. Eduard Nazmiev is involved in R&D following macro economic trends, oversees global expansion of Exxe Group, as well as CEO/CFO work.
More significant thing about Nazmiev’s expertise includes development of socio-economic programs, development of investment programs and intellectual property, and has organized management structures, manufacturing and operational systems.
Dr. Eduard Nazmiev currently holds positions of Associate Professor and Head of Economics Laboratory and Management of Academy of Sciences as well as Deputy Chief Editor of the Scientific Journal for Regional Economics.
Boris Matsokhin
Managing Director, Strategy
Boris performs the role of Managing Director, Strategy and leverages his years of expertise and experience as a senior executive in multiple industries and as a serial entrepreneur. Boris has over 20 years of experience, he held positions with Merrill Lynch, Goldman Sachs and Bloomberg, along with broad expertise in health care, technology, and real estate. His diverse experience includes leading ventures in music, film and fashion industries. He has vast experience in structuring middle market M&A deals across a broad spectrum of industries. He holds board positions in multiple ventures leveraging it to the advantage of Exxe Group
Joseph Cohen
Software development
Joseph has more than 20 years’ experience in system architecture design and management. Leading product development for Privatis, Joseph directs a team of software/mobile developers. Accomplished for his in- depth knowledge of the core programming languages required to build IT systems and platforms, Joseph co-authored The Web Programmer’s Desk Reference (2005). A graduate of California State University, Northridge, Joseph holds a Bachelor of Science in Business Administration and Finance.
Anna Ivanchenko
Chief Marketing Officer
Ms. Ivanchenko has almost 25 years of international marketing experience in senior leadership roles in largest CPG companies like MARS & DIAGEO with a proven track record across developed and emerging markets.
Anna brings significant expertise in marketing strategy, consumer and customer marketing, business & organizational transformations, development and coaching of high-profile teams for overall leadership and marketing functional capabilities.
For more than 10 years Anna was a member of Leadership teams and Management teams heading the Marketing Division. Anna earned a Bachelor and a Master’s degree in Economics.
Tiberius Vadan
Vice-President, Mergers & Acquisitions
A Harvard graduate, Mr. Vadan has over 20 years as a senior executive specializing in Mergers, Acquisitions, Divestitures, and cross-functional transformation. In his current role as Executive and partner in IBM’s Global Enterprise Transformation, he guides IBM and Fortune Global Top 50 executives on setting strategy, identifying & prioritizing transformation opportunities, determining value and identifying targets, performing due diligence and assessing risks, executing transactions, and integrating operations. He has delivered results in over 250 deals ranging in valuation size from $ 100M to $ 250B with significant financial impact.
Andrew Dickinson
Automotive
Andrew has over 10 years in the retail automotive sector. Andrew has had key involvement in every aspect of retail automotive, having spent years as the platform director of Cox Automotive and most recently an executive in the Williams Automotive Group. Andrew also brings a wealth of knowledge in the start-up sector having started and sold multiple small businesses. The knowledge gained has allowed him to leverage working as a consultant and allow him to currently sit on the board of multiple start-ups including New Town Connections. Andrew earned a Bachelor of Arts in Economics from the University of Michigan.
Duane Fillippi
Agribusiness & Renewable Energy
Duane has two decades of experience in farming & agribusiness, in particular within North American hemp operations industry. He is currently the operator of Exxe Group’s flagship hemp operations, Flying Creek Trading, and brings his invaluable expertise to the development of Exxe Group’s agribusiness division. Duane’s other specialty is renewable energy. He managed the residential and commercial energy savings programs for SaskPower, saving over 26 GWh of electricity and reduced 8 MW of demand from 490,000 SaskPower customers. With this background, he champions Exxe Group’s initiatives in the field of Renewable energy, and provides significant contributions to the Sustainability agenda of the Company.
Peter Alexander
Architectural Design & Resorts Development
A noted landscape architectural designer and planner in dozens of countries, Mr. Alexander boasts over four decades of planning, oversight, and execution in the environmental, architecture, and energy arenas. Delineating oil from water with constant different temperatures became his signature inventive improvement. Mr. Alexander has led planning and design of projects of all sizes including high-profile, major resorts such as the Olympic Training Center in Lake Placid, New York. He currently leads the Company’s efforts in the Rhode Island project and brings his invaluable expertise in driving other projects in the agribusiness segment, as well as construction of Resorts across different countries.
Caroline Delaude
Legal Counsel, Europe
Caroline is a specialist in intellectual property and corporate law. She has been involved in consulting and litigation since January 2011. She assists clients with company set up, status change, asset devolution transactions, merger absorption, spin–off or partial contribution of assets. She is responsible for negotiations and preparation of entertainment and media-related contracts. Caroline also manages copyright litigation, trademarks, and covers other aspects of Intellectual Property. Besides that, she has a strong background and experience in company management, and monitoring of company securities according to currently binding law.
Over the past eight years, Caroline has worked for the Gemalto Company (Leader in Digital security) in different countries, in a close collaboration with banks and stock market authorities. She holds a PhD in Intellectual Property, and a Master’s Degree in Tax and Corporate Law.
Darla Gullons
Board Member, Managing Director, Special Projects
Ms. Darla Gullons oversees administrative work in Canada and special projects across selected divisions. She brings valuable experience of teamwork, and knowledge of organizational flow and specific knowledge in property management.
Previously she was a President of a real investment firm. She also held Executive and Administrative positions in Marsh & McClennan Insurance Brokers, PriceWaterhouseCoopers, and Sprung Structures International.
Peter Salladé
Board Member, Managing Director, Digital Media
Mr. Salladé is an expert in media content and media/entertainment & digital content distribution in Europe and Asia. For the last decade he has served as a consultant to key government projects in Asia, including the Beijing International Film Festival, Golden Rooster Awards International Section, 48 Hour Film Project in China, etc. For 8 years and counting he’s continued the noble work of the European Union Film Festival in China to bring culture through the Great Firewall, and now is heading up Exxe Group’s digital communities department, media content development, and distribution efforts. Mr. Salladé holds an undergraduate degree in Sociology from Brandeis University, and a Master’s degree in Interactive Telecommunications from New York University’s Tisch School of the Arts.
Joanna Filipowska
Ph.D, Board Member, Head of Biotech & Medical Sciences
Ms. Joanna Filipowska holds a PhD in Medical Sciences and has a solid research background with such prominent institutions as the Mount Sinai Hospital, NY and the City of Hope Hospital, LA County. She has a meaningful publication record in biology and biotechnology. Joanna is currently engaged in due diligence and research for the Company’s health care and biopharma initiatives.
Should I sell and join the naysayers? I was hopeful until today.
So I see $.005s today! Maybe $.006s tomorrow?
SBFM Reminder: UArizona COVID-19 Treatment Takes Next Step Toward Public Impact via License to Pharmaceutical Company
A compound developed by researchers at the R. Ken Coit College of Pharmacy moves one step closer to commercialization with licensing agreement.
https://healthsciences.arizona.edu/newsroom/news-releases/0223/uarizona-covid-19-treatment-takes-next-step-toward-public-impact-license
February 28, 2023
A study conducted by researchers at the University of Arizona Health Sciences and the University of Illinois found that viral loads of the SARS-CoV-2 virus can be reduced by small molecule PLpro inhibitors. Researchers at the University of Arizona R. Ken Coit College of Pharmacy have been developing and measuring the effectiveness of a new compound that inhibits SARS-CoV-2, the virus that causes COVID-19, and the university has exclusively licensed the technology to Sunshine Biopharma Inc. to take the technology forward for further development and testing.portrait of greg thatcher Greg Thatcher, PhD, is the R. Ken and Donna Coit Endowed Chair in Drug Discovery and a professor of pharmacology and toxicology at the R. Ken Coit College of Pharmacy.
The invention is a PLpro protease inhibitor that has shown to be effective in tests performed by the development team. PLpro helps viruses avoid the human immune response and is needed for the virus to replicate. Studies have shown that the invention significantly reduces viral loads and thus is an excellent therapeutic strategy for the next generation of COVID-19 antiviral medications.
Tech Launch Arizona, the office of UArizona that commercializes inventions stemming from research, has been working with pharmaceutical company Sunshine Biopharma Inc. (NASDAQ: “SBFM”) to develop pathways to bring the invention to the public. The license grants Sunshine Biopharma worldwide rights for the University of Arizona and University of Illinois Chicago patent rights pertaining to PLpro protease inhibitors of SARS-CoV-2 developed by the researchers.
“It is good to see the work that we started at the beginning of the pandemic is moving forward towards real-world impact,” said Gregory Thatcher, PhD, professor of pharmacology and toxicology at the Coit College of Pharmacy.portrait of rui xiong
Rui Xiong is an assistant professor of pharmacology and toxicology at the R. Ken Coit College of Pharmacy.
Dr. Thatcher led the initiative in collaboration with College of Pharmacy assistant professor Rui Xiong, PhD, and postdoctoral research associate Zhengnan Shen, PhD, at the University of Arizona Health Sciences and collaborators Kiira Ratia, PhD, Lijun Rong, PhD, and Laura Cooper, PhD, at the University of Illinois Chicago.
“A strength of our research enterprise within our college is collaboration,” said Rick Schnellmann, PhD, dean of the Coit College of Pharmacy. “Cultivating partnerships only helps to advance the science aimed at solving our society’s most pressing health issues.”
“We are delighted to partner with Sunshine in the translation of this technology for the benefit of patients someday,” said Tech Launch Arizona Director of Licensing and Intellectual Property Rakhi Gibbons.
“The encouraging research results we have obtained in our collaboration with the University of Arizona prompted us to exercise our option to license,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are very pleased with this milestone in terms of securing the intellectual property of the project as we continue to move forward with the development of our COVID-19 treatment pipeline,” he added.
Specifically, the licensed patents cover small molecules which have been shown to be efficient inhibitors of PLpro – the second viral protease responsible for the suppression of the human immune system – thereby reducing the capability of the SARS-CoV-2 to cause severe illness. Paxlovid®, an inhibitor for the first protease (Mpro), has recently received emergency use authorization from the FDA. Sunshine Biopharma believes that an inhibitor for the second protease will provide another target to combat the virus and help mitigate the occurrence of possible resistance events.
CONTACT
Paul Tumarkin
Tech Launch Arizona
520-626-8770
pault@tla.arizona.edu
University of Arizona Health Sciences
TUCSON CAMPUS
Health Sciences Innovation Building (HSIB)
1670 E. Drachman St. | Tucson, Arizona 85721 | (520) 626-1197
PHOENIX CAMPUS
Health Sciences Education Building (HSEB)
475 North 5th St. | Phoenix, AZ 85004 | (602) 827-2002
Did these 2 items below occur and was this the outcome?
- If the Department determines that a request to process documentation related to a SEA Rule 10b-17 Action or a Other Company-Related Action is deficient, FINRA staff shall provide written notice to the Requesting Party. Any notice issued under this paragraph shall state the specific factor(s) that caused the request to be deemed deficient and the Requesting Party may appeal a determination pursuant to paragraph (e) of this Rule.
- Am I required to file an appeal to a FINRA Rule 6490(d) deficiency determination?
No. A requesting party is not required to appeal a deficiency finding. If a requesting party does not appeal a deficiency finding, the Department will not announce the requesting party’s Company Related Action.
Is this the week for the great AXXA turnaround? On the launchpad from $.004s to $.04s?
Why is CCAJ "Pink Limited Information" if they have such a good CEO and have an Auditor? What is going on here?
I'm getting a bit restless, even though planning to hang on the edge until 2024! I want to see if they can actually build anything since they are "a Builder primarily engaged in the construction of single-family houses (SIC 6552) and other buildings for sale" after all!
Now you can use those dividends to go to the Serenity Lakeside Resort in Thailand!
FINRA Information (below). Happy reading and I wonder where CCAJ is at in this process? Here is what CCAJ posted on their website under FAQs on March 31, 2023: "CCAC has been in contact with FINRA in regards to the Reverse Split and FINRA has made certain request in which the company is gathering the information requested to provide to FINRA."
FINRA Rule 6490. Processing of Company-Related Actions
(a) General
(1) In furtherance of FINRA's obligations to foster cooperation and coordination of the clearing, settling and processing of transactions in equity and debt securities of any issuer with a class of publicly traded, non-exchange listed, securities in the OTC market and, in general, to protect investors and the public interest, FINRA's Operations Department ("Department") reviews and processes documents related to announcements for SEA Rule 10b-17 Actions and Other Company-Related Actions to facilitate the orderly trading and settlement of OTC securities.
(2) For purposes of this Rule, the term "SEA Rule 10b-17 Actions" includes, dividends or other distributions in cash or kind, stock splits or reverse stock splits, or rights or other subscription offerings, and such other actions as are provided for in SEA Rule 10b-17; and the term "Other Company-Related Actions" includes, but is not limited to, any issuance or change to a symbol or name, mergers, acquisitions, dissolutions or other company control transactions; and bankruptcy or liquidations.
(3) This Rule details the advance notification, supporting documentation and fees required by FINRA to process documentation related to such requests.
(b) Request for FINRA Action
(1) An issuer or other duly authorized representative of the issuer may request that FINRA process documentation related to an SEA Rule 10b-17 Action or Other Company-Related Action by submitting a signed request in the manner and form required by FINRA ("Requesting Party"). Initial symbol set up requests may also be submitted by members or associated persons of members in order to comply with regulatory reporting requirements.
(2) All requests to process documentation related to an SEA Rule 10b-17 Action must be complete and submitted to the Department, in the manner and form required, no later than the time frame specified in SEA Rule 10b-17. A Requesting Party that does not submit a completed request to the Department, in the manner and form required, within the time frame specified in SEA Rule 10b-17, shall be deemed "late" and, as set forth in this Rule, subject to an additional fee before the request may be processed. Nothing in the Rule shall alter the obligations of an issuer under SEA Rule 10b-17 and the processing of documentation related to a "late" SEA Rule 10b-17 Action request by FINRA shall not relieve an issuer of any violations under such rule.
(3) All requests to process documentation related to Other Company-Related Actions must be complete and submitted to the Department, in the manner and form required, no later than the time period prescribed for such Other Company-Related Action by FINRA. Notice and information submitted for Other Company-Related Actions must be submitted no later than 10 calendar days prior to the effective date of the company action. A Requesting Party that does not submit a completed FINRA action form to the Department, in the manner and form prescribed, at least ten (10) calendar days prior to the proposed effective date of the company action, shall be deemed "late" and as set forth in this Rule, subject to an additional fee before being processed.
(4) The Department may request such additional information or documentation as may be necessary for the Department to review the request to process documentation related to an SEA Rule 10b-17 Action or Other Company-Related Action and verify the accuracy of the information submitted.
(c) Fees
The Requesting Party shall pay the following non-refundable fees for the review and processing of documentation related to an SEA Rule 10b-17 Action and Other Company-Related Action.
(d) Procedures for Reviewing Submissions
(1) Review
The Department shall review all requests to process documentation related to SEA Rule 10b-17 Actions and Other Company-Related Actions that are submitted pursuant to this Rule, including any additional documents or information requested in accordance with paragraph (b) above. All such requests must be accompanied by proof of payment of the requisite fee when appropriate in accordance with paragraph (c) above.
(2) Lapsed Requests
Where a Requesting Party does not, in the reasonable determination of the Department, sufficiently respond to any request by the Department for additional information or documentation pursuant to paragraph (b)(3) above within 90 calendar days following such Department request, such party's request shall be deemed "lapsed" and be closed.
(3) Deficiency Determination
In circumstances where an SEA Rule 10b-17 Action or Other Company-Related Action is deemed deficient, the Department may determine that it is necessary for the protection of investors, the public interest and to maintain fair and orderly markets, that documentation related to such SEA Rule 10b-17 Action or Other Company-Related Action will not be processed. In instances where the Department makes such a deficiency determination, the request to process documentation related to the SEA Rule 10b-17 Action or Other Company-Related Action, as applicable, will be closed, subject to paragraphs (d)(4) and (e) of this Rule. The Department shall make such deficiency determinations solely on the basis of one or more of the following factors: (1) FINRA staff reasonably believes the forms and all supporting documentation, in whole or in part, may not be complete, accurate or with proper authority; (2) the issuer is not current in its reporting requirements, if applicable, to the SEC or other regulatory authority; (3) FINRA has actual knowledge that the issuer, associated persons, officers, directors, transfer agent, legal adviser, promoters or other persons connected to the issuer or the SEA Rule 10b-17 Action or Other Company-Related Action are the subject of a pending, adjudicated or settled regulatory action or investigation by a federal, state or foreign regulatory agency, or a self-regulatory organization; or a civil or criminal action related to fraud or securities laws violations; (4) a state, federal or foreign authority or self-regulatory organization has provided information to FINRA, or FINRA otherwise has actual knowledge indicating that the issuer, associated persons, officers, directors, transfer agent, legal adviser, promoters or other persons connected with the issuer or the SEA Rule 10b-17 Action or Other Company-Related Action may be potentially involved in fraudulent activities related to the securities markets and/or pose a threat to public investors; and/or (5) there is significant uncertainty in the settlement and clearance process for the security.
(4) Notice Regarding Determination
If the Department determines that a request to process documentation related to a SEA Rule 10b-17 Action or a Other Company-Related Action is deficient, FINRA staff shall provide written notice to the Requesting Party. Any notice issued under this paragraph shall state the specific factor(s) that caused the request to be deemed deficient and the Requesting Party may appeal a determination pursuant to paragraph (e) of this Rule.
(5) Notice Issuance
A notice issued under this paragraph shall be issued by facsimile or electronic mail, or pursuant to Rule 9134.
(e) Request for an Appeal to Subcommittee of Uniform Practice Code Committee
A Requesting Party issued a notice under this Rule may appeal a determination made under paragraph (d)(3) of this Rule to a three-member subcommittee composed of current or former industry members of FINRA's Uniform Practice Code Committee in writing via electronic mail, unless an alternative method of service is ordered by the Adjudicator, within seven calendar days after service of the notice. Service of the appeal by electronic mail shall be deemed complete upon sending. The written request for an appeal must be accompanied by proof of payment of the non-refundable Action Determination Appeal Fee. A request for an appeal must set forth with specificity any and all defenses to the Department's determination that a request was unacceptable or otherwise deficient. An appeal to the subcommittee shall operate to stay the processing of the company-related action (i.e., the requested company-related action shall not be processed during the period that the Requesting Party requests an appeal or while any such appeal is pending). Once a written appeal has been received, the Requesting Party may submit any additional supporting written documentation via electronic mail, unless an alternative method of service is ordered by the Adjudicator, up until the time the appeal is considered by the subcommittee. The subcommittee shall convene once each calendar month to consider all appeals received under this Rule during the prior month. The subcommittee shall render a determination within three business days following the day the appeal is considered by the subcommittee. The subcommittee's determination shall constitute final action by FINRA. The subcommittee's determination shall not constitute an estoppel as to FINRA nor bind FINRA in any subsequent administrative, civil, or disciplinary proceeding. If the Requesting Party fails to file a written request for an appeal within seven calendar days after service of the notice by the Department, the Department's determination shall constitute final action by FINRA.
Below are General Questions related to Deficiency Determinations:
8. How will I know if my Company-Related Action was processed or found deficient?
FINRA will provide a written notice to the requesting party setting forth the outcome of FINRA’s review. In addition, if FINRA determines that the request will not be processed pursuant to FINRA Rule 6490(d)(3), the written notice will state the specific factor(s) that caused the request to be deemed deficient.
9. Is a FINRA Rule 6490 Company-Related Action deficiency determination a matter of public record?
No. FINRA does not publicly announce deficiency determinations relating to a Company-Related Action.
10. Will I be informed of a potential deficiency before a deficiency determination letter is issued?
Yes. Department staff will inform a requesting party of a potential deficiency before a deficiency determination is issued. The requesting party may provide the Department staff with any additional documentation intended to address the potential deficiency basis.
11. Can I appeal a deficiency determination?
Yes. A requesting party may appeal a deficiency determination within seven calendar days after service of the notice of a deficiency determination by FINRA. The written request for an appeal must be accompanied by proof of payment of the non-refundable Action Determination Appeal Fee ($4,000) and must set forth with specificity any and all defenses to the deficiency determination.
An appeal will operate to stay the processing of the Company-Related Action (i.e., the requested Company-Related Action will not be processed during the period that the requesting party’s appeal is pending). A requesting party may submit any additional supporting written documentation up until the time the appeal is considered by the subcommittee (see question 12 below for more information about the subcommittee). The subcommittee will consider the appeal based solely on the written documents submitted by the requesting party and FINRA. The submission of new facts that address the concerns in the deficiency letter, however, will not serve as a basis to reverse the Department’s decision. If there are new facts that FINRA is requested to consider in reviewing the Company-Related Action request, the requesting party should submit that information to the Department as part of a new request.
Please see Rule 6490(e) (Request for an Appeal to Subcommittee of Uniform Practice Code Committee) for additional information on the appeal process.
12. Who reviews deficiency appeals under FINRA Rule 6490?
Appeals of a deficiency determination under FINRA Rule 6490 are reviewed by a three-member subcommittee comprised of current or former industry members of FINRA’s Uniform Practice Code Committee.
13. When can I expect my appeal to be reviewed by the subcommittee?
The subcommittee convenes once each calendar month to consider all appeals received during the prior month and renders a determination within three business days following the day the appeal is considered. The subcommittee’s determination constitutes final FINRA action.
14. Am I required to file an appeal to a FINRA Rule 6490(d) deficiency determination?
No. A requesting party is not required to appeal a deficiency finding. If a requesting party does not appeal a deficiency finding, the Department will not announce the requesting party’s Company Related Action.
A lot of low priced therapeutic stocks are going back up this month on high volume trading, so the vibe seems to be a good leading indicator for SBFM to follow in the not too distant future. If SBFM continues the buyback and puts out some positive news within the next couple of months I think a return to the $2-5 price range is possible by the end of 2023. Based on this vibe I'm accumulating a bit more SBFM in the sub $1 range.
PS: Note that SBFM has recently updated their website so I think their IR/PR firm (TraDigital) is getting them ready for some growth.
Are they running it from their HQ in New York..........
Address: EXXE Group 1345 Avenue of the Americas, 2nd Floor, New York, NY 10105
Wrong...it is a 4-bit Vitamin and Prescription Drug Reseller.....and an 8-bit COVID and CANCER Drug Developer!
How many shares of it do you own?
How long have you been following this dangling carrot? Looks like about 21 days and 19 posts. How much longer will you follow?
So maybe $.30 this year, $1 next year, then up from there. Looking forward to where AXXA lands in 2023.